skip to main content

Diabetic kidney disease with clinically significant renal function deterioration after ACE inhibitor dose esca

Instant feedback + full explanation. One question, done properly.

HardNephrologyDiabetic kidney disease with clinically significant renal function deterioration after ACE inhibitor dose escalationMSRA

A 63-year-old man with type 2 diabetes, hypertension and CKD G3a A3 due to diabetic kidney disease is reviewed 12 days after ramipril was increased from 5 mg to 10 mg once daily. He also takes dapagliflozin 10 mg once daily, which has been unchanged for 9 months. Before the ramipril increase, his creatinine was 112 micromol/L, eGFR 54 mL/min/1.73 m² and potassium 4.6 mmol/L. His current BP is 142/84 mmHg. He is clinically euvolaemic and has no postural symptoms, vomiting, diarrhoea, fever or reduced oral intake. He has not taken NSAIDs, over-the-counter medicines or herbal products. There has been no recent contrast exposure. Today, creatinine is 157 micromol/L, eGFR 38 mL/min/1.73 m², potassium 5.3 mmol/L and bicarbonate 24 mmol/L. His urine ACR remains 86 mg/mmol. He has no symptoms of uraemia or hyperkalaemia. What is the most appropriate next management step?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Reduce ramipril to the previously tolerated 5 mg dose, investigate the renal deterioration and arrange early repeat renal function and potassium testing

Explanation lettering: C = shown as B · B = shown as C · E = shown as D · D = shown as E

Ramipril is indicated because he has diabetes, CKD and significant albuminuria, but the renal response to dose escalation is outside the acceptable range. Creatinine has increased by about 40% (112 to 157 micromol/L) and eGFR has fallen by about 30% (54 to 38 mL/min/1.73 m²). NICE advises investigation for reversible causes when creatinine rises by 30% or more, or eGFR falls by 25% or more, after starting or increasing a renin–angiotensin system antagonist. If no cause is found, the drug should be stopped or reduced to a previously tolerated dose. His euvolaemia and absence of NSAID exposure make a simple haemodynamic or drug-interaction explanation less likely, so renovascular disease and other causes should be considered. B would be appropriate only for a creatinine rise below 30% or eGFR fall below 25%. C is excessive: permanent withdrawal is not required when a previously tolerated lower dose is available. D prioritises BP reduction while leaving a potentially clinically significant drug-associated renal deterioration unaddressed. E is not the best immediate action: NICE referral criteria require a sustained decline, whereas this acute change follows a recent dose increase and requires medication review and investigation first.

Reference: NICE NG203: Chronic kidney disease: assessment and management — recommendations 1.6.15 and 1.6.21–1.6.23 (2021; current page checked August 2026) — https://www.nice.org.uk/guidance/ng203/chapter/Recommendations NICE NG203: Chronic kidney disease: assessment and management — PDF recommendations (2026) — https://www.nice.org.uk/guidance/ng203/resources/chronic-kidney-disease-%20assessment-and-management-pdf-66143713055173